EV-302: Patient-Reported Outcomes from EV+Pembro in mUC

BCG with gemcitabine was linked to strong early oncological efficacy and safety in previously treated patients with non–muscle-invasive bladder cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, 2025.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Studies from Munich University highlighted quality of life in bladder and prostate cancer at ASCO 2025 Genitourinary Cancers Symposium.

Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen deprivation therapy, per real-world study data.